Spark Therapeutics, Inc. (ONCE) Reaches $51.03 After 4.00% Down Move; CURE PHARMACEUTICAL HOLDING CORPORATION (CURR) Shorts Up By 7.55%

February 8, 2018 - By Marie Mckinney

CURE PHARMACEUTICAL HOLDING CORPORATION (OTCMKTS:CURR) had an increase of 7.55% in short interest. CURR’s SI was 5,700 shares in February as released by FINRA. Its up 7.55% from 5,300 shares previously. With 34,000 avg volume, 0 days are for CURE PHARMACEUTICAL HOLDING CORPORATION (OTCMKTS:CURR)’s short sellers to cover CURR’s short positions. The stock decreased 2.10% or $0.03 during the last trading session, reaching $1.4. About 30,646 shares traded. CURE Pharmaceutical Holding Corp. (OTCMKTS:CURR) has 0.00% since February 8, 2017 and is . It has underperformed by 16.70% the S&P500.

The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) is a huge mover today! The stock decreased 6.61% or $3.61 during the last trading session, reaching $51.03. About 634,118 shares traded. Spark Therapeutics, Inc. (NASDAQ:ONCE) has risen 13.53% since February 8, 2017 and is uptrending. It has underperformed by 3.17% the S&P500.The move comes after 7 months negative chart setup for the $1.89B company. It was reported on Feb, 8 by Barchart.com. We have $48.99 PT which if reached, will make NASDAQ:ONCE worth $75.52M less.

Analysts await Spark Therapeutics, Inc. (NASDAQ:ONCE) to report earnings on February, 28. They expect $-1.74 earnings per share, down 42.62% or $0.52 from last year’s $-1.22 per share. After $-1.90 actual earnings per share reported by Spark Therapeutics, Inc. for the previous quarter, Wall Street now forecasts -8.42% EPS growth.

Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company has market cap of $1.89 billion. The Company’s products include voretigene neparvovec, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or biallelic mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia. It currently has negative earnings. The companyÂ’s products also comprise SPK-7001 that is in Phase 1/2 trial for choroideremia; SPK-9001, which is in Phase 1/2 trial for hemophilia B; and SPK-8011 that is in Phase 1/2 trial hemophilia A.

Investors sentiment increased to 2.94 in 2017 Q3. Its up 1.13, from 1.81 in 2017Q2. It improved, as 17 investors sold Spark Therapeutics, Inc. shares while 19 reduced holdings. 46 funds opened positions while 60 raised stakes. 33.64 million shares or 23.59% more from 27.22 million shares in 2017Q2 were reported. Alyeska Inv Grp Lp holds 151,621 shares or 0.11% of its portfolio. Great West Life Assurance Can has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE). Credit Suisse Ag has 67,405 shares for 0.01% of their portfolio. Citadel Limited Liability Corp, a Illinois-based fund reported 13,623 shares. Cornerstone Capital Management Holdg Ltd Llc holds 0.01% or 11,089 shares. Rhumbline Advisers reported 30,390 shares. Prelude Cap Mgmt Ltd Liability Com holds 0.02% or 2,220 shares. Teacher Retirement Systems Of Texas reported 0% of its portfolio in Spark Therapeutics, Inc. (NASDAQ:ONCE). Pacad Inv accumulated 0% or 200 shares. Amundi Pioneer Asset accumulated 59,292 shares. Sei has 0% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 93 shares. Tower Cap Llc (Trc) holds 0.02% in Spark Therapeutics, Inc. (NASDAQ:ONCE) or 2,962 shares. Swiss National Bank & Trust owns 0.01% invested in Spark Therapeutics, Inc. (NASDAQ:ONCE) for 51,400 shares. Orbimed Advsrs Lc reported 0.37% in Spark Therapeutics, Inc. (NASDAQ:ONCE). 476,750 were accumulated by Wells Fargo Mn.

Among 22 analysts covering Spark Therapeutics (NASDAQ:ONCE), 15 have Buy rating, 2 Sell and 5 Hold. Therefore 68% are positive. Spark Therapeutics had 58 analyst reports since August 21, 2015 according to SRatingsIntel. On Friday, September 2 the stock rating was initiated by Stifel Nicolaus with “Buy”. As per Wednesday, September 2, the company rating was downgraded by Zacks. The firm has “Underperform” rating given on Tuesday, January 16 by Wedbush. On Friday, August 25 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The company was maintained on Tuesday, October 10 by BMO Capital Markets. The stock of Spark Therapeutics, Inc. (NASDAQ:ONCE) has “Hold” rating given on Thursday, June 2 by Jefferies. As per Monday, December 11, the company rating was maintained by Cantor Fitzgerald. BMO Capital Markets maintained it with “Buy” rating and $67.0 target in Tuesday, January 2 report. On Monday, September 4 the stock rating was maintained by Jefferies with “Buy”. The rating was maintained by Stifel Nicolaus with “Buy” on Wednesday, August 2.

Cure Pharmaceutical Holding Corp., a specialty pharmaceutical and bioscience company, develops advanced oral thin films for the delivery of nutraceutical, over-the-counter , and prescription products for human and veterinary markets. The company has market cap of $33.53 million. It offers macustrip vitamin complex, ID life sleep melatonin, electrolyte, E6 berry caffeine, and hang-over relief products. It currently has negative earnings. The firm is also developing aspirin, loratadine, tadalifil, sildenafil, loperamide, vitamin B12, vitamin D3, and folic acid products.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>